Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $12 to $14.
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $12 to $14.